Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells

Cancer

Volumn 80, Issue 8, 1997, Pages 1457-1463

  Fishman, David A ^a   Bafetti, Lisa M ^a   Banionis, Saulis ^a   Kearns, Alicia S ^a   Chilukuri, Krishna ^a   Stack, M Sharon ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Extracellular matrix; Matrix metalloproteinases; Ovarian carcinoma; Plasminogen activators; Proteinase; Tumor metastasis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INVASION; CLINICAL ARTICLE; ENZYME ACTIVITY; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0030882679     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971015)80:8<1457::AID-CNCR13>3.0.CO;2-4     Document Type: Article

References (20)

1. Hoskins WJ. Prospective on ovarian cancer. J Cell Biochem 1995;Suppl 23:189-99.
2. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44:139-66.
3. Mignatti P, Rifkin D. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73:161-95.
4. Moser TL, Enghild JJ, Pizzo SV, Stack MS. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem J 1995; 307:867-73.
5. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC, Stack MS. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 1994; 56:552-9.
6. Young TN, Rodriguez GC, Moser TL, Bast RC Jr., Pizzo SV, Stack MS. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol 1994; 170:1285-96.
7. Young TN, Pizzo SV, Stack MS. A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2. J Biol Chem 1995; 270:999-1002.
8. Young TN, Rodriguez GC, Rinehart AR, Bast RC Jr., Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 1996: 62:89-99.
9. Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC Jr. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer: relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol 1991; 164:745-50.
10. Moser TL, Pizzo SV, Bafetti LM, Fishman DA, Stack MS. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2 beta1 integrin. Int J Cancer 1996; 67:695-701.
11. Casslen B, Gustvasson B, Astedt B. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumors. Eur J Cancer 1991; 27:1445-8.
12. Pujade-Lauraine H, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A, et al. The plasminogen activation system in ovarian tumors. Int J Cancer 1993; 55:27-31.
13. Kuhn W, Pache L, Schmalfeld B, Dettma P, Schmidtt M, Janicke F, et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 1994; 55:401-9.
14. Schmalfeldt B, Kuhn W, Pache RL, Dettmar P, Schmit M, Janick F, et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 1995; 55:3958-63.
15. Chambers SK, Gertz RE, Ivins CM, Kacinski BM. The significance of urokinase-type plasminogen activator, its inhibitors and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 1995; 75:1627-33.
16. Autio-Harmainen H, Karttunen T, Hurskainen T, Hoyhtya M, Kauppila A, Tryggvason K. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest 1993; 69:312-21.
17. Naylor MS, Stamp GW, Davies BD, Balkwill, FR. Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer 1994; 58:50-6.
18. Afzal S, Lalani EN, Foulkes WD, Boyce B, Tickle S, Cardillo MR, et al. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 1996; 74:406-21.
19. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53:2087-91.
20. Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 1997; 16:150-9.